Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 21;20(1):97.
doi: 10.1186/s12967-022-03236-7.

Immune cell profiles of patients with interstitial cystitis/bladder pain syndrome

Affiliations

Immune cell profiles of patients with interstitial cystitis/bladder pain syndrome

Robert M Moldwin et al. J Transl Med. .

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a disorder characterized by bladder pain upon filling which severely affects quality of life. Clinical presentation can vary. Local inflammatory events typify the clinical presentation of IC/BPS patients with Hunner lesions (IC/BPS-HL). It has previously been proposed that B cells are more prevalent in HL, but understanding their exact role in this environment requires a more complete immunological profile of HL. We characterized immunological dysfunction specifically in HL using immunohistochemistry. We detected significantly more plasma cells (50× increase, p < 0.0001), B cells (28× increase, p < 0.0001), T cells (3× increase, p < 0.0001), monocytes/macrophages (6× increase, p < 0.0001), granulocytes (4× increase, p < 0.0001), and natural killer cells (2× increase, p = 0.0249) in IC/BPS patients with HL than in unaffected controls (UC). Patients with IC/BPS-HL also had significantly elevated urinary levels of IL-6 (p = 0.0054), TNF-α (p = 0.0064) and IL-13 (p = 0.0304) compared to patients with IC/BPS without HL (IC/BPS-NHL). In contrast, IL-12p70 levels were significantly lower in the patients with HL than in those without these lesions (p = 0.0422). Different cytokines were elevated in the urine of IC/BPS patients with and without HL, indicating that different disease processes are active in IC/BPS patients with and without HL. Elevated levels of CD138+, CD20+, and CD3+ cells in HL are consistent B and T-cell involvement in disease processes within HL.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Cystoscopic images of Hunner Lesions (HL) from 2 different patients with Interstitial Cystitis/Bladder Pain Syndrome with Hunner Lesions (IC/BPS-HL) compared to healthy bladder tissue. HLs are typically circumscribed, reddened mucosal areas with small vessels radiating towards a central scar and are seen in about 5 to 10 percent of patients with IC/BPS [4]. Diagnosis is made via cystoscopy and confirmed by biopsy
Fig. 2
Fig. 2
A Images of biopsied tissues from patients with Interstitial Cystitis/Bladder Pain Syndrome with Hunner Lesions (IC/BPS-HL) and unaffected controls (UC) stained for immune cell markers. Cross sections of bladder urothelium viewed at ×40 magnification and stained for Hematoxylin and Eosin (H&E, nucleus/cytoplasm), CD3 (pan T cells), CD20 (B cells), CD138 (plasma cells), CD14 (monocytes), and CD15 (neutrophils/eosinophils). Biopsies were performed on 48 patients diagnosed with IC/BPS-HL and 2 unaffected controls (UC). Thin (4–6 µm) cross sections of bladder tissue were then stained with either H&E or specific CD markers. Images of Hunner lesions and control tissue are shown. B Average cell marker counts found in the bladder biopsy samples of patients with IC/BPS-HL vs. UC. Cells positive for each marker were quantified per high-dry field (×400), taken in the area of maximum diffuse infiltration by the inflammatory cells. Data are expressed as mean ± SEM. C Relative proportions of cells displaying each cell marker in UC and IC/BPS-HL cohorts. The average proportion of Cluster of Differentiation (CD)-20 positive (CD20+) B cells (IC/BPS-HL: 12%; UC: 2%) and CD138+ plasma cells (IC/BPS-HL: 21%; UC: 2%) was much greater in pooled samples from patients with IC/BPS-HL compared to pooled samples from unaffected controls, while the percentage of Natural Killer cells (IC/BPS-HL: 7%; UC: 15%), Monocytes (IC/BPS-HL: 18%; UC: 15%), and Neutrophils (IC/BPS-HL: 14%; UC: 13%) did not differ significantly between the two cohorts. The relative abundance of cells displaying the CD3 T cell marker fell from 52% among the unaffected controls to 29% among the IC/BPS-HL cohort
Fig. 3
Fig. 3
Urinary Cytokine concentrations in patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), and unaffected controls (UC). Nine cytokines (Interferon-γ, Interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-12p70, IL-13, and Tumor Necrosis Factor-α) were assessed using a MSD U-plex 10 spot assay (Mesoscale discovery, Catalog # K15049K-1). Individual and average (indicated by the horizontal bar) cytokine concentrations for A IL-6, B TNF-α, C IL-12p70, and D IL-13 from patients with Interstitial Cystitis/Bladder Pain Syndrome without Hunner Lesions (IC/BPS-NHL), patients with Interstitial Cystitis/Bladder Pain Syndrome without Hunner Lesions (IC/BPS-HL), and UC research participants. Data are expressed as mean ± SEM

References

    1. Duh K, et al. Crosstalk between the immune system and neural pathways in interstitial cystitis/bladder pain syndrome. Discov Med. 2018;25(139):243–250. - PubMed
    1. Keller JJ, Chen YK, Lin HC. Comorbidities of bladder pain syndrome/interstitial cystitis: a population-based study. BJU Int. 2012;110(11 Pt C):E903–E909. doi: 10.1111/j.1464-410X.2012.11539.x. - DOI - PubMed
    1. Hanno PM, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–1553. doi: 10.1016/j.juro.2015.01.086. - DOI - PubMed
    1. Whitmore KE, et al. Hunner lesion versus non-Hunner lesion interstitial cystitis/bladder pain syndrome. Int J Urol. 2019;26(Suppl 1):26–34. doi: 10.1111/iju.13971. - DOI - PubMed
    1. van de Merwe JP. Interstitial cystitis and systemic autoimmune diseases. Nat Clin Pract Urol. 2007;4(9):484–491. doi: 10.1038/ncpuro0874. - DOI - PubMed

Publication types